Penn State Launches Novel Clinical Trial Targeting NASH with Exercise & No Pharmaceuticals

Penn State Launches Novel Clinical Trial Targeting NASH with Exercise & No Pharmaceuticals

Penn State researchers developed a first-of-its-kind clinical trial to investigate the impact of exercise on a severe form of nonalcoholic fatty liver disease. This study precludes drugs as they are often ineffective and trigger side effects in NASH patients. Called the NASH Fitness Intervention in Thrombosis or NASHFit, the study design itself was showcased recently in the journal Contemporary Clinical Trials Communications. Will investigative teams increasingly look to more holistic, preventive modes of study with less dependence on drugs?

What is NASH?

Nonalcoholic fatty disease represents the leading cause of chronic liver disease in the United States, and as TrialSite News has reported on in the past, represents a not-well-known but emerging health crisis on the scale of type 2 diabetes.

This disease originates from the accumulation of fat build up, unrelated to alcohol use, in patient’s liver cells. The disease often emerges as a comorbidity associated with individuals struggling with significant weight challenges and obesity, diabetes or high cholesterol.

In its severe progression, the disease becomes nonalcoholic steatohepatitis or NASH. If a patient with NASH ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee